Investment Rating - The report maintains a "Buy" rating for Kelun Biotech [2][16] Core Insights - Kelun Biotech reported a revenue of RMB 2.06 billion for 2025, representing a year-on-year growth of 6.5%, with a net loss of RMB 382 million, which is an increase of 43.2% year-on-year [5][12] - The adjusted net loss for 2025 was RMB 211 million, reflecting a year-on-year increase of 78.3%, aligning with expectations [5][12] - The company achieved product sales of RMB 543 million in 2025, a significant increase of 949.8% year-on-year, while revenue from business development collaborations decreased by 19.6% to RMB 1.5 billion [5][12] Financial Data and Profit Forecast - The company’s R&D expenses rose by 9.4% to RMB 1.32 billion, and selling expenses surged by 160.1% to RMB 475 million, resulting in a selling expense ratio of 23.1% for 2025 [5][12] - As of the end of 2025, Kelun Biotech had cash and financial assets amounting to approximately RMB 4.56 billion [5][12] - Revenue projections for the upcoming years are as follows: - 2026: RMB 2.7 billion (31.25% growth) - 2027: RMB 4.8 billion (77.64% growth) - 2028: RMB 6.5 billion (34.74% growth) [10][17] Product Pipeline and Market Position - The company has four commercialized products, including Sac-TMT, which is expected to see significant sales growth due to its inclusion in the National Reimbursement Drug List (NRDL) [6][13] - Sac-TMT has received NMPA approval for multiple indications and several pivotal clinical trials have been initiated, including for advanced solid tumors [7][14] - The pipeline includes various innovative ADCs and dual antibodies, with ongoing clinical trials for several promising candidates [8][15] Target Price and Earnings Forecast - The target price for Kelun Biotech has been raised from HKD 552 to HKD 560, indicating a potential upside of 31% [16] - Earnings per share (EPS) forecasts have been adjusted, with estimates for 2026 revised down to -RMB 0.57 and for 2027 to RMB 2.26, while a new forecast for 2028 is set at RMB 6.61 [16]

Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Insights - The company reported a revenue of 33.56 billion and a net profit of 5.887 billion for the year 2025, representing a year-on-year growth of 35.16% and 32.69% respectively [5] - The company is focusing on a multi-brand strategy, with plans to upgrade products and enhance store operations in key cities [6][9] - The company has nearly 60,000 stores globally, with a strategic adjustment in domestic store openings and optimization of overseas operations [7] Financial Performance - The company's gross margin and net profit margin for 2025 were 31.1% and 17.7%, respectively, showing a slight decline compared to the previous year [8] - The forecast for revenue from 2026 to 2028 is projected to be 38.599 billion, 42.197 billion, and 45.424 billion, with year-on-year growth rates of 15%, 9%, and 8% respectively [9][11] - The expected net profit for the same period is 6.64 billion, 7.381 billion, and 8.179 billion, with growth rates of 13% for 2026 and 11% for the following years [9][11]

Investment Rating - The report upgrades the investment rating of the company to "Strong Buy" with a target price of HKD 55.23, indicating a potential upside of 38% from the current price of HKD 40.10 [2][6]. Core Insights - The company achieved a revenue of USD 1.35 billion in 2025, representing a year-on-year growth of 13.1%. Aircraft revenue grew by 12.5% to USD 1.15 billion, while service and other revenue increased by 17% to USD 203 million, accounting for 15% of total revenue [6][7]. - The company delivered 797 aircraft in 2025, a 9% increase year-on-year, with a market share of 24.7%, up by 1.6 percentage points [6]. - The average selling price of aircraft rose by 3.2% to USD 1.45 million in 2025, reflecting the company's ability to maintain pricing power [6]. - The company has a robust order backlog of 1,066 aircraft, including approximately 221 Vision Jet orders, indicating strong demand and production capacity [6]. - The report highlights the company's unique safety features, such as the patented whole-aircraft parachute system and the emergency auto-landing system, which enhance customer appeal [6]. Financial Summary - The company’s net profit for 2025 was USD 139 million, a 15% increase year-on-year, with an adjusted profit also at USD 139 million, reflecting a 12.5% growth [6]. - The gross margin for 2025 was 35.2%, an increase of 0.7 percentage points year-on-year, while the net margin was 10.3%, up by 0.2 percentage points [6]. - The report projects revenue growth of 14% in 2026, with net profit expected to reach USD 161 million, reflecting a 16.1% increase [7]. - The company’s price-to-earnings (P/E) ratio is projected to decrease from 14 in 2025 to 9 by 2028, indicating a potential undervaluation compared to peers [7].

Investment Rating - The investment rating for Anta Sports is "Buy" [6] Core Views - Anta Sports is expected to achieve a revenue growth of 13.3% to 80.219 billion yuan in 2025, with a net profit growth of 13.9% after excluding one-time gains [1] - The company emphasizes shareholder returns with a dividend payout ratio of 50.1% [1] - The multi-brand strategy is showing significant advantages, with strong performance expected from various brands under the Anta umbrella [1][12] Revenue Summary - Anta brand revenue is projected to grow by 3.7% to 34.754 billion yuan in 2025, driven by channel and product optimization [2] - Fila brand revenue is expected to increase by 6.9% to 28.469 billion yuan in 2025, showcasing resilience in a fluctuating environment [4] - Other brands, including Descente and Kolon Sport, are anticipated to see a revenue growth of 59.2% to 16.996 billion yuan in 2025 [11] Profitability Summary - Anta brand's operating profit margin is stable at 20.7%, despite a slight decline in gross margin to 53.6% [3] - Fila brand's operating profit margin improved to 26.1%, even with a decrease in gross margin to 66.4% [5] - The overall profitability of other brands is expected to maintain an operating profit margin between 25% and 30% [11] Financial Projections - For 2026, Anta Sports is projected to achieve a net profit of approximately 14.053 billion yuan, with revenue growth expected in the high single digits [13] - The company anticipates a net profit of 15.653 billion yuan in 2026, reflecting a growth of about 3% [13] - The projected P/E ratio for 2026 is 13 times, with further growth expected in 2027 and 2028 [13]

Investment Rating - The report maintains a "Buy" rating for Haidilao [1] Core Views - Haidilao achieved a revenue of 43.23 billion yuan in 2025, a year-on-year increase of 1.1%, while the net profit attributable to shareholders was 4.05 billion yuan, a decrease of 14% [4][5] - The company is focusing on the "Pomegranate Plan" in 2026 to enhance operational efficiency and brand diversification [8][9] - The overall net profit margin for 2025 was 9.4%, down by 1.6 percentage points year-on-year, primarily due to changes in cost structure [7] Revenue Performance - In 2025, the revenue breakdown included restaurant operations at 37.54 billion yuan, takeout at 2.66 billion yuan, other restaurant operations at 1.52 billion yuan, and franchise operations at 0.27 billion yuan, with respective year-on-year changes of -7.1%, +111.9%, +214.6%, and +1518.7% [5] - The overall customer unit price for 2025 was 97.7 yuan, showing a slight increase from 97.5 yuan in 2024 [6] Cost Structure - In 2025, raw material costs accounted for 40.5% of revenue, an increase of 2.6 percentage points year-on-year, while employee costs represented 32.6%, a decrease of 0.5 percentage points [7] - The company maintained a high dividend payout ratio, proposing a final dividend of 0.384 HKD per share for 2025, resulting in a total payout ratio of approximately 87% [7] Future Outlook - The company plans to enhance table turnover rates by focusing on product quality, increasing new product launches, and improving customer experience through digitalization and differentiated store formats [8] - Haidilao's net profit forecasts for 2026 and 2027 are 4.80 billion yuan and 5.30 billion yuan, respectively, with expected earnings per share (EPS) of 0.86 yuan and 0.95 yuan [9]

Investment Rating - The report maintains a "Strong Buy" rating for Mengniu Dairy (02319.HK) with a target price of HKD 24 [2][6]. Core Views - The company reported a decline in revenue and profits for 2025, with total revenue of HKD 82.245 billion, down 7.25% year-on-year, and a net profit of HKD 1.545 billion, a significant increase from HKD 0.105 billion in the previous year [2][6]. - The second half of 2025 saw a continued decline in revenue for liquid milk, while other segments like milk powder and cheese showed positive growth, indicating a mixed performance across product lines [2][6]. - The report highlights a recovery potential for 2026, driven by improved market conditions and a reduction in inventory levels, suggesting that the company may return to profitability in the near term [2][6]. Financial Summary - **2025 Financial Performance**: - Total revenue: HKD 82.245 billion, down 7.25% YoY - Operating profit: HKD 6.564 billion, down 9.54% YoY - Net profit attributable to shareholders: HKD 1.545 billion, up from HKD 0.105 billion YoY [2][6]. - **2026-2028 Projections**: - Expected revenue growth: - 2026: HKD 86.159 billion (4.8% growth) - 2027: HKD 89.280 billion (3.6% growth) - 2028: HKD 92.152 billion (3.2% growth) [2][6]. - Projected net profit: - 2026: HKD 4.960 billion - 2027: HKD 5.570 billion - 2028: HKD 6.269 billion [2][6]. - **Valuation Metrics**: - Price-to-Earnings (P/E) ratio for 2026 is projected at 11 times, with a dividend yield of approximately 3.7% [2][6]. Segment Performance - **Liquid Milk**: Revenue for 2025 was HKD 649.4 billion, down 11.1% YoY, with expectations of recovery in 2026 [2][6]. - **Milk Powder**: Revenue increased by 9.7% in 2025, driven by strong brand performance in the domestic market [2][6]. - **Cheese**: Revenue growth of 21.9% in 2025, indicating strong demand and market positioning [2][6]. Shareholder Returns - The company announced a shareholder return plan for 2025-2027, with total dividends expected to increase from HKD 20.17 billion in 2025, up from HKD 19.91 billion in 2024 [2][6]. Market Outlook - The report suggests that the company is well-positioned for recovery in 2026, with improving market conditions and a focus on expanding its product offerings internationally [2][6].

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of HKD 12 [2][6]. Core Views - The company reported a significant decline in financial performance for 2025, with total revenue of HKD 3.65 billion, down 48.3% year-on-year, and a net profit of HKD 538 million, down 59.3% [2][6]. - The second half of 2025 saw an even sharper decline, with revenue dropping 60.7% to HKD 1.15 billion and a negative net profit of HKD -0.4 billion [2][6]. - The company is focusing on inventory reduction and channel rationalization, which has led to a substantial clearing of its financial statements [2][6]. - For 2026, the company anticipates a recovery, with projected revenue growth of 10.3% and a Non-GAAP net profit increase of 10.5% [2][6]. Financial Summary - **2025 Financial Performance**: - Total Revenue: HKD 3,650 million - Year-on-Year Change: -48.3% - Net Profit: HKD 538 million - Year-on-Year Change: -59.3% - Non-GAAP Net Profit: HKD 523 million - Year-on-Year Change: -68.8% [2][7] - **2026-2028 Projections**: - 2026 Revenue: HKD 4,027 million (10.3% growth) - 2027 Revenue: HKD 4,822 million (19.7% growth) - 2028 Revenue: HKD 5,519 million (14.5% growth) - 2026 Net Profit: HKD 595 million (10.5% growth) - 2027 Net Profit: HKD 704 million (18.3% growth) - 2028 Net Profit: HKD 939 million (33.4% growth) [2][7]. Market Position and Strategy - The company is implementing a new sales strategy through the "Wanshang Alliance," which has signed over 4,000 partners, with positive feedback on the new product "Dazhen" [2][6]. - The company is also focusing on upgrading its existing products, such as "Xiaozhen" with a new pricing strategy aimed at the mid-range market [2][6]. - The report highlights the importance of innovation and channel management in navigating the current industry challenges [2][6].

Investment Rating - The report maintains a "Buy" rating for Kelun Biotech [2][16] Core Insights - Kelun Biotech reported a revenue of RMB 2.06 billion for 2025, representing a year-on-year growth of 6.5%, with a net loss of RMB 382 million, which is an increase of 43.2% year-on-year [5][12] - The adjusted net loss for 2025 was RMB 211 million, reflecting a year-on-year increase of 78.3%, aligning with expectations [5][12] - The company achieved product sales of RMB 543 million in 2025, a significant increase of 949.8% year-on-year, while revenue from business development collaborations decreased by 19.6% to RMB 1.50 billion [5][12] - R&D expenses rose by 9.4% to RMB 1.32 billion, and selling expenses surged by 160.1% to RMB 475 million, resulting in a selling expense ratio of 23.1% [5][12] Financial Data and Profit Forecast - The company expects revenue growth to continue, with projected revenues of RMB 2.70 billion in 2026, RMB 4.80 billion in 2027, and RMB 6.47 billion in 2028, reflecting growth rates of 31.25%, 77.64%, and 34.74% respectively [10][18] - The forecasted net profit for 2026 is a loss of RMB 132 million, with a turnaround expected in 2027 with a profit of RMB 528 million and RMB 1.54 billion in 2028 [10][18] - The earnings per share (EPS) forecast for 2026 is adjusted to a loss of RMB 0.57, with a projected profit of RMB 2.26 in 2027 and RMB 6.61 in 2028 [10][16] Product Pipeline and Market Position - Kelun Biotech has four commercialized products, including Sac-TMT, which is expected to see significant sales growth due to its inclusion in the National Reimbursement Drug List (NRDL) [6][13] - The company has initiated multiple pivotal clinical trials for Sac-TMT, targeting various cancers, and has received NMPA approval for its use in specific indications [7][14] - The pipeline includes a rich array of oncology and non-oncology products, with several in different stages of clinical trials, indicating a strong focus on innovation and market expansion [8][15]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a total revenue of 37.12 billion yuan in 2025, representing a year-on-year growth of 184.71%, and a net profit attributable to shareholders of 12.78 billion yuan, which is a 308.76% increase year-on-year [8] - The company's overseas revenue surged to 16.27 billion yuan, marking a 291.9% increase, with the overseas revenue proportion rising from 31.8% in 2024 to 43.8% in 2025 [8] - The gross margin improved by 5.3 percentage points to 72.1%, driven by an increase in overseas revenue, enhanced bargaining power from a flexible supply chain strategy, and a decrease in the proportion of licensing and mold fees [8] - The company continues to expand its IP matrix, with six IPs generating over 2 billion yuan in revenue and 17 IPs exceeding 100 million yuan [8] - The report projects an increase in Non-IFRS net profit forecasts for 2026 and 2027, raising the estimates to 17.4 billion yuan and 21.8 billion yuan respectively, with a new forecast for 2028 at 26.1 billion yuan [8] Financial Summary - Total revenue forecast for 2026 is 47.54 billion yuan, with a year-on-year growth of 28.08% [9] - The projected net profit for 2026 is 16.69 billion yuan, reflecting a growth rate of 30.62% [9] - The company's P/E ratio is expected to decrease from 15.56 in 2025 to 11.91 in 2026, indicating an attractive valuation [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company achieved a net profit attributable to shareholders of HKD 14.519 billion in 2025, a slight increase of 0.9% compared to 2024, slightly exceeding market expectations [7] - The growth in 2025 was primarily driven by a decline in coal prices and new investment projects, while the performance of renewable energy was affected by changes in accounting estimates [7] - The company plans to enhance its operational efficiency and quality during the "14th Five-Year Plan" period, focusing on clean and efficient coal power, renewable energy, and integrated energy services [7] Financial Performance Summary - Revenue projections for the company are as follows: - 2024: HKD 105.283 billion - 2025: HKD 102.005 billion (down 3.11%) - 2026E: HKD 105.688 billion (up 3.61%) - 2027E: HKD 109.004 billion (up 3.14%) - 2028E: HKD 112.687 billion (up 3.38%) [6] - Net profit attributable to shareholders is projected as follows: - 2024: HKD 14.388 billion - 2025: HKD 14.519 billion (up 0.9%) - 2026E: HKD 11.361 billion (down 21.7%) - 2027E: HKD 12.691 billion (up 11.7%) - 2028E: HKD 14.002 billion (up 10.3%) [6] - The company’s return on equity (ROE) is expected to be 9.8% in 2026, with a price-to-earnings (P/E) ratio of 8.8 for 2026 [6] Operational Data Summary - As of the end of 2025, the company managed a total installed capacity of 104.12 million kW, with a rights-based installed capacity of 89.65 million kW, split evenly between thermal and renewable energy [7] - The company plans to add 5.45 million kW of wind and solar capacity in 2026, focusing on integrated energy services as a new growth engine [7] - The average utilization hours for 2025 were reported as follows: - Wind: 2307 hours (down 1% YoY) - Solar: 1296 hours (down 8.4% YoY) - Coal: 4299 hours (down 6.4% YoY) [7]